Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 971569, 10 pages
http://dx.doi.org/10.1155/2014/971569
Research Article

In Silico Molecular Docking and In Vitro Antidiabetic Studies of Dihydropyrimido[4,5-a]acridin-2-amines

1Chemistry Research Laboratory, Organic Chemistry Division, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu 632 014, India
2Bioinformatics Division, School of Bio Sciences and Technology, VIT University, Vellore, Tamil Nadu 632 014, India
3Division of Industrial Biotechnology, School of Bio Sciences and Technology, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu 632 014, India

Received 19 February 2014; Revised 18 March 2014; Accepted 1 April 2014; Published 2 June 2014

Academic Editor: Kota V. Ramana

Copyright © 2014 A. Bharathi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R.J. Milling and C.J. Richardson, “Mode of action of the anilino-pyrimidine fungicide pyrimethanil. 2. Effects on enzyme secretion in Botrytis cinerea,” Pesticidal Science, vol. 45, no. 1, pp. 33–48, 2006. View at Google Scholar
  2. M. Y. Liu and D. Q. Shi, “Synthesis and herbicidal activity of 2-aroxy-propanamides containing pyrimidine and 1, 3, 4-thiadiazole rings,” Journal of Heterocyclic Chemistry, vol. 51, no. 2, pp. 432–435, 2014. View at Publisher · View at Google Scholar
  3. J. L. Bernier, J. P. Henichart, V. Warin, and F. Baert, “Synthesis and structure-activity relationship of a pyrimido[4,5-d]pyrimidine derivative with antidepressant activity,” Journal of Pharmaceutical Sciences, vol. 69, no. 11, pp. 1343–1345, 1980. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Gong, F. Hong, C. Kohm et al., “Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: Inhibitors of lysophosphatidic acid acyltransferase-β,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 9, pp. 2303–2308, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. L. S. Jeong, L. X. Zhao, W. J. Choi et al., “Synthesis and antitumor activity of fluorocyclopentenyl-pyrimidines,” Nucleosides, Nucleotides, and Nucleic Acids, vol. 26, no. 6-7, pp. 713–716, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Hawser, S. Lociuro, and K. Islam, “Dihydrofolate reductase inhibitors as antibacterial agents,” Biochemical Pharmacology, vol. 71, no. 7, pp. 941–948, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Lee, K.-H. Kim, and S. Jeong, “Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 14, pp. 4203–4205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. V. R. Gadhachanda, B. Wu, Z. Wang et al., “4-Aminopyrimidines as novel HIV-1 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 1, pp. 260–265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Hocková, A. Holý, M. Masojídková et al., “5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy) ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity,” Journal of Medicinal Chemistry, vol. 46, no. 23, pp. 5064–5073, 2003. View at Google Scholar · View at Scopus
  10. B. M. Rezk, G. R. M. M. Haenen, W. J. F. Van Der Vijgh, and A. Bast, “Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore,” FEBS Letters, vol. 555, no. 3, pp. 601–605, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Kitamura, A. Hikita, H. Ishikawa, and A. Fujimoto, “Photoinduced amino-imino tautomerization reaction in 2-aminopyrimidine and its methyl derivatives with acetic acid,” Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 62, no. 4-5, pp. 1157–1164, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Xie, H. Zhao, L. Zhao, L. Lou, and Y. Hu, “Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 1, pp. 275–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. D. Jones, D. M. Andrews, A. J. Barker et al., “Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 24, pp. 6486–6489, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. Y.-S. Seong, C. Min, L. Li et al., “Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026,” Cancer Research, vol. 63, no. 21, pp. 7384–7391, 2003. View at Google Scholar
  15. M. A. Vilchis-Reyes, A. Zentella, M. A. Martínez-Urbina et al., “Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives,” European Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 379–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Capdeville, E. Buchdunger, J. Zimmermann, and A. Matter, “Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug,” Nature Reviews Drug Discovery, vol. 1, no. 7, pp. 493–502, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. P.-P. Kung, M. D. Casper, K. L. Cook et al., “Structure-activity relationships of novel 2-substituted quinazoline antibacterial agents,” Journal of Medicinal Chemistry, vol. 42, no. 22, pp. 4705–4713, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Singh, S. K. Pandey, N. Anand et al., “Synthesis, molecular modeling and bio-evaluation of cycloalkyl fused 2-aminopyrimidines as antitubercular and antidiabetic agents,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 15, pp. 4404–4408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Singh, H. Kaur, K. Chibale, J. Balzarini, S. Little, and P. V. Bharatam, “2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies,” European Journal of Medicinal Chemistry, vol. 52, pp. 82–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Nagaraj and C. Sanjeeva Reddy, “Synthesis and biological study of novel bis-chalcones, bis-thiazines and bis-pyrimidines,” Journal of the Iranian Chemical Society, vol. 5, no. 2, pp. 262–267, 2008. View at Google Scholar · View at Scopus
  21. N. Kumar, A. Chauhan, and S. Drabu, “Synthesis of cyanopyridine and pyrimidine analogues as new anti-inflammatory and antimicrobial agents,” Biomedicine and Pharmacotherapy, vol. 65, no. 5, pp. 375–380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. H. Kwon, H. J. Park, N. Chitrapriya et al., “Effect of number and location of amine groups on the thermodynamic parameters on the acridine derivatives to DNA,” The Bulletin of the Korean Chemical Society, vol. 34, no. 3, pp. 810–814, 2013. View at Google Scholar
  23. L. S. LERMAN, “The structure of the DNA-acridine complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 49, pp. 94–102, 1963. View at Google Scholar · View at Scopus
  24. H. Kubinyi, “Combinatorial and computational approaches in structure-based drug design,” Current Opinion in Drug Discovery and Development, vol. 1, no. 1, pp. 16–27, 1998. View at Google Scholar · View at Scopus
  25. S. Amuthalakshmi and A. Anton Smith, “Insilico design of a ligand for DPP IV in type II diabetes,” Advances in Biological Research, vol. 7, no. 6, pp. 248–252, 2013. View at Google Scholar
  26. P. Z. Zimmet, “Diabetes epidemiology as a tool to trigger diabetes research and care,” Diabetologia, vol. 42, no. 5, pp. 499–518, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. H. P. Rang, M. M. Dale, J. M. Ritter, and P. K. Moore, Pharmacology Churchill Living Stone, 5th edition, 2003.
  28. M. R. Kandadi, P. K. Rajanna, M. K. Unnikrishnan et al., “2-(3,4-Dihydro-2H-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a novel, synthetic small molecule that alleviates insulin resistance and lipid abnormalities,” Biochemical Pharmacology, vol. 79, no. 4, pp. 623–631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Shashikant, P. Kekareb, P. Ashwini, and A. Nikaljec, “Studies on the synthesis of novel 2,4-thiazolidinedione derivatives with antidiabetic activity,” Iranian Journal of Pharmaceutical Sciences, vol. 5, no. 4, pp. 225–230, 2009. View at Google Scholar
  30. R. Subashini, A. Bharathi, S. Mohana Roopan, and G. Rajakumar, “Synthesis, spectral characterization and larvicidal activity of acridin-1(2H)-one analogues,” Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 95, pp. 442–445, 2012. View at Google Scholar
  31. G. L. Miller, “Use of dinitrosalicylic acid reagent for determination of reducing sugar,” Analytical Chemistry, vol. 31, no. 3, pp. 426–428, 1959. View at Google Scholar · View at Scopus
  32. A. M. Gray and R. R. Flatt, “Nature's own pharmacy: the diabetes perspective,” Proceedings of the Nutrition Society, vol. 56, no. 1B, pp. 507–517, 1997. View at Publisher · View at Google Scholar
  33. G. Ramírez, M. Zavala, J. Pérez, and A. Zamilpa, “In vitro screening of medicinal plants used in Mexico as antidiabetics with glucosidase and lipase inhibitory activities,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 701261, 6 pages, 2012. View at Publisher · View at Google Scholar
  34. P. Senthil Kumar and S. Sudha, “Evaluation of α-amylase or α-glucosidase inhibitory prosperities of selected seaweeds from gulf of mannar,” International Research Journal of Pharmacy, vol. 3, no. 8, pp. 128–130, 2012. View at Google Scholar
  35. A. Pedretti, L. Villa, and G. Vistoli, “VEGA: an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming,” Journal of Computer-Aided Molecular Design, vol. 18, no. 3, pp. 167–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, and J. J. P. Stewart, “AM1: a new general purpose quantum mechanical molecular model,” Journal of the American Chemical Society, vol. 107, no. 13, pp. 3902–3909, 1985. View at Google Scholar · View at Scopus
  37. E. Kashani-Amin, B. Larijani, and A. E. Habibi, “Neohesperidin dihydrochalcone, presentation of a small molecule activator of mammalian alpha-amylase as an allosteric effector,” FEBS Letter, vol. 587, pp. 652–658, 2013. View at Google Scholar
  38. G. M. Morris, D. S. Goodsell, R. S. Halliday et al., “Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function,” Journal of Computational Chemistry, vol. 19, no. 14, pp. 1639–1662, 1998. View at Google Scholar · View at Scopus
  39. T. Liu, Y. M. Yip, L. Song, and S. Feng, “Inhibiting enzymatic starch digestion by the phenolic compound diboside A: a mechanistic and in silico study,” Food Research International, vol. 54, pp. 595–600, 2013. View at Publisher · View at Google Scholar
  40. L. J. Scott and C. M. Spencer, “Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus,” Drugs, vol. 59, no. 3, pp. 521–549, 2000. View at Google Scholar · View at Scopus
  41. A. Y. Y. Cheng and I. G. Fantus, “Oral antihyperglycemic therapy for type 2 diabetes mellitus,” Canadian Medicinal Association Journal, vol. 172, no. 2, pp. 213–226, 2005. View at Publisher · View at Google Scholar · View at Scopus